Embody vs GoodRx (Foundayo + Zepbound KwikPen)
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Embody
Best for lowest first-month entry pricing on compounded GLP-1sStarting at $99/mo
GoodRx (Foundayo + Zepbound KwikPen)
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmaciesStarting at $149/mo
Side-by-Side Comparison
| Feature | Embody | GoodRx (Foundayo + Zepbound KwikPen) |
|---|---|---|
| Overall Score | ✓8.5/10 | 8.4/10 |
| Starting Price | ✓$99/mo | $149/mo |
| Editorial Rating | ✓4.3 ★ /5 | 4.2 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | ✓50 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Embody
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
GoodRx (Foundayo + Zepbound KwikPen)
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
Our Verdict
Embody edges out GoodRx (Foundayo + Zepbound KwikPen) with a higher overall score of 8.5/10 and is particularly strong for lowest first-month entry pricing on compounded GLP-1s. GoodRx (Foundayo + Zepbound KwikPen) remains a solid alternative, especially if you're looking for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.